Floodlight Open is a new global study using Roche and Genentech’s proprietary Floodlight mobile technology to collect and monitor anonymized patient data to help gain a better understanding of MS disease progression. The Floodlight mobile technology assesses sensor-based outcomes from a series of active neurological tests and passive monitoring through the use of patients’ smartphones. 

An ongoing pilot study, most recently presented at the 2018 American Academy of Neurology Annual Meeting, supports the Floodlight mobile technology as a potential complement to in-clinic testing that may provide a more complete and consistent picture of a patient’s underlying disease activity and its effect on disability progression. Floodlight Open is an observational, open access study aimed to enroll 10,000 people globally, including people with relapsing and progressive forms of MS, within five years. Data will be available through an open access database that is accessible to the entire MS research community. 

For more information on the Floodlight Open study and how to enroll, visit www.floodlightopen.com.